Abbott Meridia sNDA Extends Use of Obesity Agent From One Year To Two
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Labeling for Abbott’s obesity agent Meridia (sibutramine) has added two-year maintenance data, following approval of a supplemental NDA Feb. 16. The approval gives the drug data on length of treatment equal to that in labeling for Roche’s competing agent Xenical (orlistat).
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class